Table 1.
Recently approved biosimilars for inflammatory diseases
| Biologic | Originator brand name (manufacturer) | Biosimilar brand name (manufacturer) |
|---|---|---|
| Infliximab | Remicade (Janssen Biotech, Horsham, PA, USA, and Janssen Biologics B.V., Leiden, the Netherlands). | Remsima (Celltrion Healthcare Hungary Kft, Budapest, Hungary)a Flixabi (Samsung Bioepis, Chertsey, UK) |
| Etanercept | Enbrel (Amgen Inc., Thousand Oaks, CA, USA, and Pfizer Inc, Sandwich, UK [EU]). | Benepali (Samsung Bioepis, Chertsey, UK) |
Note:
a
Remsima is also marketed as Inflectra (Hospira, Maidenhead, UK) in the EU.
Abbreviation: EU, European Union.